Last week, Fresenius Kabi, a subsidiary of Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS) said it was looking into the possibility
of acquiring Akorn, Inc. (NASDAQ: AKRX).
Since the announcement, shares of the latter have spiked more than 30 percent, currently trading close to $32.75.
In a report issued Monday, Leerink analysts Jason M. Gerberry and Etzer Darout weighed in on the issue, arguing that Akorn
complements
Fresenius and that a competitive bidding for the former seems unlikely. The experts set an estimated takeout valuation of $32–$34
per share, based on comparable deal multiples.
This target implies very little to zero upside potential from current stock prices; on the other hand, if the deal does not
materialize, the downside potential comes in double digits – as Leerink values the company at roughly $22 or $23 per share.
Akorn’s Contribution
According to the research report, Gerberry and Darout believe Akorn would provide Fresenius with “an expanded injectable
business and a top US generic ophthalmic business while adding a few other specialty dosage forms.”
From the acquirer’s perspective, the purchase would add a few cost synergies, estimated at around $100 million.
Having said this, they noted that both companies pay very elevated tax rates of approximately 31 percent, so, “it's unclear if
financial synergies are a driving force behind the potential acquisition.”
Related Links:
What Success Is Made Of:
Investors, Execs And Entrepreneurs Talk Routines And Role Models
Exclusive: TriPoint Global Equities And BANQ® CEO On The JOBS Act, Bringing Small-Cap IPOs And Capital Formation Back To Individual
Investors
Latest Ratings for AKRX
Date |
Firm |
Action |
From |
To |
Mar 2017 |
Deutsche Bank |
Downgrades |
Buy |
Hold |
Dec 2016 |
Goldman Sachs |
Initiates Coverage On |
|
Sell |
Nov 2016 |
Deutsche Bank |
Upgrades |
Hold |
Buy |
View More Analyst Ratings for
AKRX
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.